Published in Eur J Clin Pharmacol on January 01, 1986
Clinical pharmacology, physiology and pathophysiology of superficial veins--2. Br J Clin Pharmacol (1994) 0.96
Dihydroergotamine: discrepancy between arterial, arteriolar and pharmacokinetic data. Br J Clin Pharmacol (2001) 0.76
beta-Adrenoceptor blocking activity and duration of action of pindolol and propranolol in healthy volunteers. Br J Clin Pharmacol (1976) 2.17
A new technique for recording compliance of human hand veins. Br J Clin Pharmacol (1981) 1.80
Blood levels of practolol following intravenous administration. Br J Pharmacol (1970) 1.61
Pharmacokinetics of SMS 201-995 in healthy subjects. Scand J Gastroenterol Suppl (1986) 1.36
Isoprenaline antagonism and duration of action in exercise induced tachycardia of three -adrenoceptor blocking drugs: pindolol, LF 17-895 and propranolol. Br J Pharmacol (1973) 1.35
The role of D-1 and D-2 receptors. Nature (1980) 1.24
Simultaneous modeling of bopindolol kinetics and dynamics. Clin Pharmacol Ther (1984) 1.22
Comparative pharmacokinetic investigations with tritium-labeled ergot alkaloids after oral and intravenous administration man. Int J Clin Pharmacol Biopharm (1977) 1.19
Venoconstrictor effect of dihydroergotamine in superficial hand veins. Eur J Clin Pharmacol (1974) 1.15
The influence of beta-adrenoceptor blocking drugs with and without intrinsic sympathomimetic activity on the hormonal responses to hypo- and hyperglycaemia. Br J Clin Pharmacol (1982) 1.15
[Peripheral circulatory effects of ergotamine, dihyroergotamine and 1-methylergotamine on the innevated, perfused hindlimb of the o]. Helv Physiol Pharmacol Acta (1967) 1.11
9-10-dihydroergotamine: production of antibodies and radioimmunoassay. Experientia (1976) 1.09
Pindolol--a beta-adrenoceptor blocking drug with partial agonist activity: clinical pharmacological considerations. Br J Clin Pharmacol (1982) 1.08
Pharmacological experiments in healthy volunteers with bopindolol, a long-acting beta-adrenoceptor blocking drug with partial agonist activity. Br J Clin Pharmacol (1985) 1.08
The action of intravenous oxprenolol, practolol, propranolol and sotalol on acute exercise tolerance in angina pectoris: the effect on heart rate and the electrocardiogram. Postgrad Med J (1970) 1.03
Duration of action and plasma levels of beta-adrenoceptor blocking drugs. Arch Int Pharmacodyn Ther (1980) 0.95
Prolonged action of pindolol. Br Med J (1973) 0.94
Purification and properties of histidine decarboxylase from Lactobacillus 30a. Proc Natl Acad Sci U S A (1965) 0.94
Intravenous diazepam in minor oral surgery. Further studies. Br Dent J (1970) 0.91
Use of a linear variable differential transformer to measure compliance of human hand veins in situ [proceedings]. Br J Clin Pharmacol (1979) 0.91
Clinical pharmacology of pindolol. Am Heart J (1982) 0.91
Ergot alkaloids: hepatic distribution and estimation of absorption by measurement of total radioactivity in bile and urine. J Pharmacokinet Biopharm (1976) 0.90
The effect of graded doses of practolol on the tachycardia induced by isoprenaline, Valsalva's manoeuvre and exercise. Br J Pharmacol (1970) 0.86
Specific 3H radioimmunoassay with a monoclonal antibody for monitoring cyclosporine in blood. Clin Chem (1988) 0.85
Investigation of the venoconstrictor effect of 8' hydroxydihydroergotamine, the main metabolite of dihydroergotamine, in man. Eur J Clin Pharmacol (1984) 0.84
Cardiac effects of adrenaline and felypressin as vasoconstrictors in local anaesthesia for oral surgery under diazepam sedation. Br J Anaesth (1970) 0.83
Relationship between plasma concentrations and cardiac beta-adrenoceptor blockade--a study with oral and intravenous bopindolol. Br J Clin Pharmacol (1986) 0.83
Interindividual variation of beta-adrenoceptor blocking drugs, plasma concentration and effect: influence of genetic status on behaviour of atenolol, bopindolol and metoprolol. Eur J Clin Pharmacol (1985) 0.83
Investigations with beta-adrenoceptor blocking drugs in healthy volunteers. Acta Med Scand Suppl (1977) 0.82
A new technique for recording compliance of human hand veins. 1981. Br J Clin Pharmacol (2004) 0.82
Studies of the effect of natural and synthetic polypeptide type ergot compounds on a peripheral vascular bed. Br J Pharmacol (1969) 0.82
Methods for studying drug effects on superficial human veins. Methods Find Exp Clin Pharmacol (1985) 0.81
Comparison of the duration of action of pindolol and slow release oxprenolol in healthy volunteers. Eur J Clin Pharmacol (1978) 0.81
Pharmacokinetic investigation of oral and i.v. dihydroergotamine in healthy subjects. Eur J Clin Pharmacol (1991) 0.81
Monoclonal antibodies for radioimmunoassay of cyclosporine: a multicenter comparison of their performance with the Sandoz polyclonal radioimmunoassay kit. Clin Chem (1988) 0.81
Significance of the goblet-cell mucin layer, the outermost luminal barrier to passage through the gut wall. Biochem Biophys Res Commun (1980) 0.80
Dihydroergotamine: pharmacokinetics, pharmacodynamics, and mechanism of venoconstrictor action in beagle dogs. J Cardiovasc Pharmacol (1987) 0.80
Plasma bromocriptine levels, clinical and growth hormone responses in Parkinsonism. Br J Clin Pharmacol (1978) 0.80
[Clinicopharmacological studies with pindolol following intravenous and oral administration]. Adv Clin Pharmacol (1976) 0.80
A pharmacodynamic and pharmacokinetic comparison of pindolol 20 mg retard and a conventional tablet. Eur J Clin Pharmacol (1981) 0.79
Ex vivo studies after oral treatment of the beagle with dihydroergotamine. Eur J Pharmacol (1983) 0.78
Studies on the venoconstrictor effect of ergot compounds in man. Triangle (1975) 0.78
Sandostatin, a new analogue of somatostatin, reduces the metabolic changes induced by the nocturnal interruption of continuous subcutaneous insulin infusion in type 1 (insulin-dependent) diabetic patients. Diabetologia (1989) 0.78
Immunoassay of ergotamine and dihydroergotamine using a common 3H-labelled ligand as tracer for specific antibody and means to overcome experienced pitfalls. Int J Nucl Med Biol (1984) 0.78
Influence of ergot compounds on compliance of superficial hand veins in man. Postgrad Med J (1976) 0.78
Ergotamine in plasma and CSF after i.m. and rectal administration to humans. Cephalalgia (1982) 0.78
Activity and duration of action of pindolol and alprenolol compared in healthy volunteers. Eur J Clin Pharmacol (1978) 0.77
Direct effects of vasoactive substances on superficial human veins in vivo. Int Angiol (1986) 0.76
Experiments with pindolol (Visken) in healthy volunteers. Med J Aust (1977) 0.76
[Effect of ergot alkaloids on venous tonus determined in superficial hand veins in situ]. Cardiology (1976) 0.75
Vasovagal faint in the supine position. Br Med J (1970) 0.75
Description of the time course of the prolactin suppressant effect of the dopamine agonist CQP201-403 by an integrated pharmacokinetic-pharmacodynamic model. Br J Clin Pharmacol (1986) 0.75
Contrasts between pindolol and propranolol concentration-response relationships. Br J Clin Pharmacol (1985) 0.75
Influence of pizotifen and ergotamine on the venoconstrictor effect of 5-hydroxytryptamine and noradrenaline in man. Eur J Clin Pharmacol (1983) 0.75
The acute exercise test for the preliminary evaluation of beta-receptor blocking drugs in angina pectoris. Br J Pharmacol (1969) 0.75
Agonists and antagonists of 5-hydroxytryptamine on venomotor receptors. Adv Neurol (1982) 0.75
A new radioimmunoassay of thioridazine and its comparison with a high performance liquid chromatographic method and another radioimmunoassay. Ther Drug Monit (1987) 0.75
[Isolation, amino composition and trypsin decomposition of thyrocalcitonin from pig thyroids]. Helv Chim Acta (1968) 0.75
Dependence of area under the curve on proquazone particle size and in vitro dissolution rate. J Pharm Sci (1980) 0.75
Pharmacokinetics of a long-acting bromocriptine preparation (Parlodel LA) and its effect on release of prolactin and growth hormone. Eur J Clin Pharmacol (1986) 0.75
Clinical pharmacology of beta-adrenoceptor blocking drugs possessing partial agonist activity, with special reference to pindolol. J Cardiovasc Pharmacol (1983) 0.75
Non-equilibrium method for the radioimmunoassay of clozapine in the presence of metabolites. Eur J Biochem (1977) 0.75
Steady state pharmacokinetics of hydrolysed bopindolol in young and elderly men. Eur J Clin Pharmacol (1991) 0.75
Pharmacokinetic comparison of pindolol 30 mg retard and 15 mg normal tablets. Eur J Clin Pharmacol (1982) 0.75
Clinical pharmacological studies with the long-acting beta-adrenoceptor blocking drug bopindolol. J Cardiovasc Pharmacol (1986) 0.75
Permanent bile duct cannulation in the monkey. A model for studying intestinal absorption. Eur J Pharmacol (1975) 0.75